Abstract Impaired brain clearance of amyloid-beta peptides (Ab) 40 and 42 across the blood-brain barrier (BBB) is believed to be one of the pathways responsible for Alzheimer's disease (AD) pathogenesis. Hyperinsulinemia prevalent in type II diabetes was shown to damage cerebral vasculature and increase Ab accumulation in AD brain. However, there is no clarity on how aberrations in peripheral insulin levels affect Ab accumulation in the brain. This study describes, for the first time, an intricate relation between plasma insulin and Ab transport at the BBB. Upon peripheral insulin administration in wild-type mice: the plasma clearance of Ab40 increased, but Ab42 clearance reduced; the plasma-to-brain influx of Ab40 increased, and that of Ab42 reduced; and the clearance of intracerebrally injected Ab40 decreased, whereas Ab42 clearance increased. In hCMEC/D3 monolayers (in vitro BBB model) exposed to insulin, the luminal uptake and luminal-to-abluminal permeability of Ab40 increased and that of Ab42 reduced; the abluminal-to-luminal permeability of Ab40 decreased, whereas Ab42 permeability increased. Moreover, Ab cellular trafficking machinery was altered. In summary, Ab40 and Ab42 demonstrated distinct distribution kinetics in plasma and brain compartments, and insulin differentially modulated their distribution. Cerebrovascular disease and metabolic disorders may disrupt this intricate homeostasis and aggravate AD pathology.
Introduction
Alzheimer's disease (AD) is characterized by amyloid beta (Ab) deposits in the brain parenchyma; intraneuronal tangles of hyperphosphorylated tau protein; neurodegeneration in the cortex and hippocampus; and impaired glucose metabolism in the brain. 1 Investigators have been targeting these hallmarks of AD pathology with an expectation to uncover novel therapeutic strategies to halt or even reverse AD progression. Among these, the reduction of brain Ab burden is widely considered to be a viable therapeutic strategy, and developing methods to promote brain Ab clearance have been at the forefront of AD research. The two-hit vascular hypothesis of AD, proposed by Zlokovic, posits that Ab accumulation in the brain is secondary and subsequent to the primary insult sustained by the cerebral vasculature. 2 There is substantial speculation on the pathological changes that are capable of delivering the first hit to the cerebral vasculature, and some of the likely suspects include hyperinsulinemia and peripheral insulin resistance, that are prevalent in type II diabetes. 3 Hyperinsulinemia is believed to engender cerebrovascular dysfunction and dampen cerebrovascular reactivity, which is critical for sustaining neuronal activity. 4 Clinically, cerebrovascular dysfunction is measured as changes in the cerebral blood flow and alterations in the permeability of the cerebrovascular endothelium, classically referred to as the blood-brain barrier (BBB). The cerebrovascular reactivity is primarily facilitated by the BBB and vascular smooth muscle in the larger vessels. But in the smaller vessels, such as capillaries that are devoid of smooth muscle cells, contractile pericytes take their place. 5 Moreover, pericytes are believed to restrict vascular permeability and maintain the BBB integrity. 6, 7 Hyperinsulinemia could lead to the degeneration of these vascular cells, cause disruptions in cerebrovascular structure and function, and lead to BBB dysfunction. 8 The BBB endothelium is a quintessential trafficking portal that delivers critical cargo, including glucose and growth factors, from plasma to brain, and clear metabolic byproducts, such as Ab peptides, from the brain. Previous studies have shown that insulin impacts plasma pharmacokinetics of Ab peptides and modulates the dynamics Ab trafficking at the BBB. [9] [10] [11] Elucidating the cellular and molecular mechanisms harnessed by insulin in order to influence Ab trafficking at the BBB in healthy animals is critical to fully realize the consequences of BBB dysfunction triggered by insulin resistance and hyperinsulinemia. Hence, the purpose of this study is to investigate the effect of insulin on the distribution kinetics of two main Ab isoforms, Ab40 and Ab42, in plasma and brain compartments, with an emphasis on the impact of insulin exposure on the Ab trafficking across the BBB endothelium.
Materials and methods

Reagents and lab supplies
Ab40 and Ab42 peptides were synthesized in the Mayo Clinic Proteomics Core (Rochester, MN) or procured from AAPPtec, LLC (Louisville, KY). The 125 I was obtained from Perkin Elmer Life and Analytical Sciences (Boston, MA). Insulin (Novolin Õ R or Humulin Õ R) was purchased from Eli Lilly (Indianapolis, IN). Plastic wares were obtained from Corning life sciences (Tewksbury, MA), USA Scientific (Ocala, FL) or Denville Scientific Inc., (South Plainfield, NJ). Plasmids were obtained from Addgene (Cambridge, MA). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless stated otherwise.
Animals
Wild-type (WT) mice (B6SJLF1) were purchased from Jackson Laboratory, Bar Harbor, ME. They were housed in Mayo Clinic animal care facility under standard conditions and provided access to food and water ad libitum. Male and female mice between ages five and eight months were used. The male and female mice were randomly distributed to various groups. The animal studies were done in a single-blinded fashion. The animal experimenters were provided with minimal details required for the experiment to be performed. In addition, they were blinded from details of the final data analysis and the study conclusions until all animal experiments were completed. All studies were conducted in accordance with the National Institutes of Health guidelines for the care and use of laboratory animals, and protocols approved by the Mayo Clinic Institutional Animal Care and Use Committee. Data in this manuscript are reported according to the ARRIVE guidelines.
Radioiodination of A peptides
As described in our previous publications, 12, 13 the Ab peptides were labeled with 125 I using the chloramine-T reaction, and the product was dialyzed to remove unconjugated 125 I. The purity of the 125 I-labeled protein was determined by trichloroacetic acid (TCA) assay.
Biodistribution of 125 I-A
B6SJLF1 mouse was anesthetized (1.5% isoflurane with 4 L/min O 2 ) and its femoral vein/artery and the internal carotid artery were catheterized. Saline (100 mL, control) or insulin (nominal dose of 1 IU, treatment) was administered via internal carotid artery over the course of 5 min. Fifteen minutes following the insulin infusion, 100 mCi of 125 I-Ab40 or 125 I-Ab42 was administered to each mouse via the femoral vein (note 125 I-Ab42: saline (n ¼ 6) and insulin (n ¼ 7); 125 I-Ab40 saline (n ¼ 3) and insulin (n ¼ 3)). A 20-mL blood sample was collected from the femoral artery at pre-determined time points (0.25, 1, 3, 5, 7, 10, and 15 min post administration of 125 I-Ab); the plasma was separated; TCA precipitated; and the radioactivity of the intact protein was measured in the pellet by a two-channel gamma counter (Cobra II; Amersham Biosciences Inc., Piscataway, NJ). Finally, the mouse was transcardially perfused with excess phosphate-buffered saline (PBS) to flush radioactivity in the blood, and the brain radioactivity was assayed.
The plasma data at each time point were analyzed by Grubb's test to remove potential statistical outliers. The average plasma data was then computed and then fitted to the following biexponential equation
and the primary parameters -A and B intercepts, as well as the a and b rate constants were estimated. The secondary parameters such as the C max (maximum plasma concentration), plasma clearance (CL), and area under the plasma concentration curve (AUC) were calculated also using WinNonlin. The influx of 125 I-Ab proteins into the brain was determined as described below:
To resolve insulin's impact on the 125 I-Ab influx in various brain regions of the left and right brain hemispheres, the experiment was conducted by infusing a higher dose of insulin (4.2 IU) over 15 min via the left internal carotid artery. Then, 100 mCi of 125 I-Ab40 or 125 I-Ab42 was administered to each mouse via the femoral vein ( 125 I-Ab42: saline (n ¼ 6) and insulin (n ¼ 5); 125 I-Ab40 saline (n ¼ 5, one outlier was excluded) and insulin (n ¼ 6, one outlier was excluded)), and the plasma was sampled from the femoral artery for the following 15 min. At the end of the experiment, each hemisphere was dissected into the cortex, hippocampus, caudate putamen, thalamus, brain stem, and cerebellum, and the radioactivity was assayed in the gamma counter.
Dynamic SPECT/CT studies to assess 125 I-A distribution in plasma and brain compartments For assessing plasma-to-brain influx, the WT mice (n ¼ 3) were infused with saline or insulin (4.2 IU) for 15 min via the internal carotid artery and then administered with 100 mCi of 125 I-Ab40 or 125 I-Ab42 through the femoral vein. The animals were immediately imaged for the following 40 min by dynamic SPECT/CT (Gamma Medica, Northridge, CA) as described previously. 13 The plasma-to-brain influx of 125 I-Ab was predicted by Gjedde-Patlak plot, [14] [15] [16] which was constructed by plotting Amount brain ðtÞ C p ðtÞ Vs:
The Amount brain denotes the brain radioactivity at time t; the R t 0 C p ð Þd is plasma AUC from the time of injection; and C p ðtÞ is instantaneous plasma activity at time ¼ t. Plasma concentrations were simulated using equation (1) , and predicted primary plasma PK parameters. The
is also referred to as exposure time.
Slope of the linear portion of the Gjedde-Patlak plot is referred to as the brain transfer rate constant (K i ).
To assess brain-to-plasma clearance, mice were administered with saline or a nominal dose of 4.2 IU insulin (four animals per group) via the internal carotid artery over 15 AE 1 min. At the end of infusion, they were injected with 1 mL of either 125 I-Ab40 or 125 I-Ab42 (about 3-4 mCi /per animal) into the right hippocampus. The animals were imaged for the following 100 min by dynamic SPECT/CT. The obtained radioactivity counts were normalized to the body weight and the administered radioactivity. Changes in the brain radioactivity (as a percent of initial levels) were plotted on the natural log scale against time and then fitted to a one-phase decay model using Prism version 5 (Graph pad software, La Jolla, CA).
Cell culture
The immortalized human cerebral microvascular endothelial cell line (hCMEC/D3) was a kind gift from P-O Couraud, Institut Cochin, France. These cells were cultured as previously described. To assess abluminal-to-luminal permeability (A-L), insulin (100 mIU/mL) and 125 I-Ab (20 mCi/mL) were added to the abluminal compartment and 20-mL samples were collected from the luminal compartment at various time intervals. A-L permeability was then calculated as described above.
DNA transfections
Cells, cultured on 6-well plates or 35-mm glass bottom culture dishes (MatTek Corp, Ashland, MA), were transfected with 1.5-2 mg of human insulin receptor plasmid (IR, Addgene plasmid #24049, 0.67 or 1.1 mg/mL in 1X Tris-EDTA buffer) using Lipofectamine LTX reagent kit (Invitrogen, Grand Island, NY). The DNA was diluted with 145 mL Opti-MEM TM (Invitrogen) and 2.5 mL of Plus reagent was added. The contents were mixed by pipetting and then transferred to another tube containing 6 mL of Lipofectamine Õ pre-diluted with 144 mL of Opti-MEM TM . The mixture was added to the cells and replaced with fresh growth media after 12 h. Then, cells were allowed to recover for 36 h before the experiment.
Impact of insulin on FITC-transferrin uptake by flow cytometry
The IR transfected cells were exposed to insulin (100 mIU/mL, 20 min) and then treated with 40 mg/mL fluorescein isothiocyanate-conjugated transferrin (FITC-transferrin) for 30 min at 37
C. The cells were harvested, fixed with 2% v/v para-formaldehyde for 15 min, and the intracellular fluorescence was measured using Accuri TM C6 flow cytometer (BD Biosciences, San Jose, CA).
Impact of insulin on Alexa Fluor
Õ 647-conjugated cholera toxin and Alexa Fluor Õ 633-conjugated transferrin by confocal microscopy
The IR transfected cells were treated with insulin (100 mIU/mL, 20 min) and then treated with Alexa Fluor 
Impact of insulin on 125 I-A exocytosis
Polarized hCMEC/D3 monolayers were cultured on 24-mm Transwell Õ inserts and exposed to 100 mIU/mL insulin for 20 min. Then, both luminal and abluminal chambers were spiked with 125 I-Ab40 or 125 I-Ab42 (10 mCi) and incubated for 1 h at 37 C. The media was removed, filter surface was washed twice with HBSS to remove non-specifically bound radioactive peptides, and then the cells were fed with growth media containing 1% FBS (control) or 100 mIU/mL insulin (treatment). Then, 50-mL sample aliquots were obtained from the luminal and abluminal chambers at 10, 20, 30, 45, 60 and 90 min, and assayed for radioactivity.
Whole cell lysis, plasma membrane fractionation, and Western blotting Whole cell lysis: Control or insulin (100 mIU/mL, 20 min)-treated cells were washed with ice-cold Dulbecco's PBS, dislodged from tissue culture dishes using a cell scrapper, pelleted and then dispersed in radioimmunoprecipitation assay buffer (RIPA, Thermo Scientific, Waltham, MA) containing EDTA-free protease inhibitor cocktail (Roche, Branford, CT). Protein lysates were obtained by a high-speed centrifugation at 9600 g, 5 min, 4 C.
Plasma membrane fractionation, western blotting, and immunocytochemistry: Methods have been detailed in the Supplementary Section.
Statistical analyses
Statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001) of the differences between the mean responses with and without insulin exposure, both in vivo as well as in vitro, was ascertained by Student's t-test using Prism version 5 (Graph pad software, La Jolla, CA). Significance (*p < 0.05, **p < 0.01, ***p < 0.001) of insulin impact on the influx of 125 I-Ab in various brain regions was evaluated by two-way ANOVA followed by Bonferroni's multiple comparison tests. In dynamic SPECT studies, F-tests were done to compare the statistical significance of the curves obtained with and without insulin exposure.
Results
Effect of insulin on the plasma pharmacokinetics of A peptides in mice
Both 125 I-Ab40 (Figure 1(a) ) and 125 I-Ab42 ( Figure  1(b) ) displayed biexponential plasma disposition in mice treated with insulin or saline. Maximal plasma concentration (C max ) and area under the curve (AUC) of 125 I-Ab40 were found to be significantly lower in insulin pre-injected animals than in control animals ( Figure 1(c) ). However, the C max and AUC of 125 IAb42 significantly increased in insulin-treated mice compared to the control mice (Figure 1(c) ). Similarly, 125 I-Ab40 clearance increased, but 125 I-Ab42 clearance decreased in insulin-treated animals compared to controls (Figure 1(c) ).
Insulin modulates the plasma-to-brain distribution of 125 I-A40 and 125 I-A42
The parameter obtained by normalizing the brain uptake of intravenously administered Figure 1) , was statistically significant compared to the control mice (Figure 2(b) ). In contrast, the influx of 125 I-Ab42 significantly decreased in the left hemisphere of insulin pre-injected mice compared to the control mice. Although similar trends were apparent in the right hemisphere, they are not statistically significant (Figure 2(b) ).
These intriguing results were further verified using dynamic SPECT imaging. The plasma-to-brain transfer rate constant (K i ) of 125 I-Ab40 was found to be higher (Figure 3(a) ), but the K i of 125 I-Ab42 was lower ( Figure 3(b) ) in the insulin-infused mice compared to saline-infused mice. The K i of 125 I-Ab40 was 4.85 AE 0.24 mL * min À 1 * 10 À3 in control mice and it increased to 5.95 AE 0.15 mL * min À1 * 10 À3 in insulintreated animals. The K i of 125 I-Ab42 was 9.97 AE 0.22 mL * min À1 * 10 À3 in control mice and it decreased to 7.92 AE 0.18 * mL * min À1 * 10 À3 in insulin-treated animals.
Insulin modulates the brain-to-plasma clearance of 125 I-A40 and 125 I-A42 in mice
Saline or insulin was infused via the internal carotid artery and then 125 I-Ab40 or 125 I-Ab42 was injected into the right hippocampus. Change in the injected radioactivity with time was monitored by SPECT/CT imaging (Figure 4(a) ). The brain elimination rate constant of 125 I-Ab40 was 0.009 AE 0.001 min À1 in control mice but decreased to 0.003 AE 0.001 min À1 in insulintreated mice (Figure 4(a), panel-i) . In contrast, the brain elimination of 125 I-Ab42 in the control mice was 0.006 AE 0.001 min À1 but increased to 0.011 AE 0.002 min À1 in mice pre-administered with insulin ( Figure 4(a), panel-ii) . Representative SPECT/CT images are presented in Figure 4 Subsequently, we investigated if the internalized 125 I-Ab isoforms are exocytosed differently from the hCMEC/D3 monolayers.
125 I-Ab40 was exocytosed to both luminal and abluminal chambers. However, the rate of exocytosis into the abluminal chamber (263.88 AE 54.81 mCi * min À1 ) was significantly greater than that into the luminal chamber (84.41 AE 7.2 mCi * min À1 ) ( Figure 5(b) , control treatments in panels-i and iii; note: Y-axis scales are different in these plots). Upon insulin treatment, the luminal exocytosis rate of 125 I-Ab40 decreased to 56.52 AE 12.20 mCi * min 
Insulin exposure triggers A receptor/transporter relocation in hCMEC/D3 monolayers
The fate of putative amyloid receptors/transporters, such as LRP-1, RAGE, SRB-1 and P-gp, 18-20 upon insulin exposure, was investigated in hCMEC/D3 cells. The levels of LRP-1, RAGE and P-gp increased in the plasma membrane fraction of insulin-treated cells compared to that of the control cells, but SRB-1 levels were not affected by the insulin exposure (Figure 6(a) , panel-i). However, insulin pre-treatment did not change the whole cell expression levels of these receptors (Figure 6(a), panel-ii) .
Subsequently, the effect of insulin on the re-distribution of Ab receptors LRP-1 and RAGE, as well P-gp efflux transporter within hCMEC/D3 monolayers was imaged by confocal microscopy ( Figure 6(b) , panels i to iii). With insulin pre-treatment, LRP-1 accumulation in the plasma membrane increased and reached the highest levels upon 20 min of insulin exposure. However, the LRP-1 immunofluorescence decreased upon further exposure to insulin for 60 min (Figure 6(b), panel-i) . 
Insulin differentially modulates clathrin and caveolae-mediated endocytosis
Several reports have implicated insulin's role in intracellular trafficking. [21] [22] [23] Reports from our lab have shown that Ab40 endocytosis is predominantly mediated by clathrin-mediated endocytosis, whereas the uptake of Ab42 is primarily mediated by caveolae-mediated endocytosis. 24 Hence, we investigated the effect of insulin on the cellular endocytosis machinery in hCMEC/D3 cells, overexpressing the insulin receptor (IR-hCMEC/D3). Insulin pre-treatment increased the uptake of AF633-Trf (a classical marker for clathrinmediated endocytosis) by 84% compared to the control cells as assessed by flow cytometry (Figure 7(a) , panels-i and ii); and similar effects were evident in the confocal micrographs (Figure 7(a), panel-iii) . However, insulin treatment decreased the uptake of AF647-CT (a marker for lipid rafts involved in caveolae-mediated endocytosis) by IR-hCMEC/D3 cell monolayers (Figure 7(b) ).
Discussion
Recent clinical trials conducted in a small group of AD patients demonstrated the efficacy of intranasally administered insulin in improving memory and restoring normal amyloid levels in the brain. 25 Encouraged by these results, researchers have begun to investigate mechanisms of insulin action in plasma and brain, in the hope of discovering novel molecular targets for AD diagnosis and treatment. These investigations have shown that the peripheral insulin administration alters plasma Ab clearance and increase Ab levels in the brain interstitial fluid, whereas the intracerebral insulin administration does not have a detectable impact on the brain Ab levels. 10 The current study has verified and further resolved these findings by establishing the ability of peripheral insulin to differentially modulate Ab40 and Ab42 transcytosis at the BBB and affect their plasma and brain disposition.
Impact of peripheral insulin on plasma 125 I-A kinetics
Exogenous insulin (1 IU) administration into systemic circulation increased the plasma clearance and decreased the plasma AUC (a parameter indicative of the extent of tissue exposure) of 125 I-Ab40 (Figure 1(a)  and (c) ). This observation agrees with the previous findings that insulin facilitates the hepatic clearance of plasma Ab40. 11 In contrast, the clearance of 125 I-Ab42 decreased, and the plasma AUC increased with insulin administration (Figure 1(b) and (c) ). The increase in plasma Ab42 levels was shown to enhance hepatic insulin resistance. 26 Thus, changes in plasma insulin levels during the circadian cycles and chronic perturbations observed in metabolic disorders could decrease Ab42 elimination from the plasma, 26 enhance its exposure to peripheral tissues, and beget peripheral insulin resistance which may exacerbate hyperinsulinemia.
Impact of insulin on brain 125 I-A kinetics
With a 15-min infusion of 1 IU insulin, the plasma-tobrain influx of 125 I-Ab40 increased, and that of 125 I-Ab42 was reduced (Figure 2(a) ). These trends were also verified by SPECT imaging. Gjedde-Patlak plots generated from the SPECT images provided estimates for the plasma-to-brain transfer rate constants (K i ) which are analogous to influx values obtained from the pharmacokinetic experiments. The K i of 125 I-Ab40 was found to be significantly greater than that of 125 I-Ab42 (Figure 3 ). At higher doses (4.2 IU), the effect of insulin was clearly resolved in right and left hemispheres as well as in the brain regions which are affected in AD (cortex, hippocampus, caudate putamen, and thalamus 27, 28 ). Insulin administered via left internal carotid artery significantly increased the influx of 125 I-Ab40 into these brain regions but reduced the influx of 125 I-Ab42 (Figure 2(b) ). Similar trends were apparent in the right hemisphere, but they are not statistically significant. Differences in the magnitude of insulin's effect on the right and left brain hemispheres could stem from differences in the insulin exposure. We estimated that the insulin infusion via the left internal carotid artery delivers twice as much insulin to the left hemisphere as to the right hemisphere within the experimental time-frame (Supplementary Figure 1) . The observed effects of insulin on brain Ab permeability are unlikely due to systemic pharmacological effects triggered by the insulin administration. If it were so, both hemispheres would have been equally affected.
Higher plasma insulin levels also differentially modulated the brain-to-plasma clearance of 125 I-Ab40 and 125 I-Ab42; the clearance of intracerebrally injected 125 I-Ab40 was inhibited (Figure 4(a), panel (i) and (b) , panels (i) and (ii)) but that of 125 I-Ab42 was enhanced in insulin-exposed animals compared to the saline-treated controls (Figure 4(a), panel (ii) and (b) , panels (iii) and (iv)). These results indicate that insulin spares Ab40, but clears more toxic and amyloidogenic Ab42 from the brain. Such changes in Ab kinetics promoted by insulin could elevate Ab40 levels and decrease relative Ab42:40 ratios in the brain, which were shown to decrease amyloidogenesis 29 and impart neuroprotection. 30 These findings are also in agreement with the recent reports that peripheral insulin administration increased the accumulation of Ab proteins in the brain interstitial fluid of APP swe /PS1DE9.
10 Although investigators of the study did not differentiate the accumulation of Ab40 from Ab42, it is easy to deduce that increase in the accumulation Ab40, which is 10 times more abundant than Ab42, could offset the decrease in Ab42 accumulation, and show a net increase in brain Ab accumulation.
Owing to beneficial effects reported by the direct nose-to-brain administration of insulin in AD patients, 25 it is important to separately consider the effects of luminal versus abluminal insulin exposure on Ab trafficking. Shiiki et al. 9 have reported that intracerebral insulin administration in WT rats impaired 125 I-Ab40 clearance from the brain. They also claimed that insulin does not affect putative Ab40 trafficking receptors such as LRP-1, but altered the proteolytic degradation of Ab40 by the insulin degrading enzyme (IDE). 9 It was purported that IDE primarily degrades monomeric Ab40, whereas the degradation of amyloidogenic Ab42 could follow multiple pathways. 31 The internal carotid insulin administration employed in this study may not facilitate enough insulin accumulation in the brain to adequately inhibit IDE and engender reduction in Ab metabolism in the brain. Moreover, the differential impact of plasma insulin observed on the cerebral clearance of Ab40 and Ab42 suggests the substantial involvement of other clearance pathways. Recently, Stanley et al. 10 have reported that intracerebral insulin administration to APP swe /PS1DE9 did not change brain Ab levels significantly. Differences in the observations made by these two groups could be due to the inability of intracerebrally injected insulin to rejuvenate already disrupted Ab clearance pathways in APP swe /PS1DE9 model and/or due to the opposing effects of insulin on the brain clearances of Ab40 and Ab42. Stanley et al. 10 did not differentiate between Ab40 and Ab42 when they assessed brain Ab accumulation by microdialysis. Thus, increase in Ab40 levels in the brain interstitial fluid (assessed) could be counteracted by the decrease in Ab42 levels, and diminish the magnitude of overall effect.
Insulin modulates Ab distribution between plasma and brain compartments, most likely by acting on the neurovascular unit, which constitutes neurons, glia (microglia and astrocytes), and vascular cells (BBB endothelium, pericytes, and vascular smooth muscle cells). 2 Insulin signaling is known to extend throughout these constituents of the neurovascular unit and is believed to regulate neurovascular function. 32, 33 Although several pathways may be involved in clearing Ab from the brain, the vascular clearance -mediated by the BBB endothelium, a highly specialized trafficking portal, and pericytes that modulate BBB signaling/ trafficking -is the most predominant. 34 Insulin signaling pathways are shown to be critical for the functional coordination and communication between the endothelium and pericytes (reviewed by Richards et al. 8 ). The deleterious consequences of hyperinsulinemia and insulin resistance -often observed in metabolic disorderson the endothelium as well as pericytes 35, 36 were shown to cause BBB dysfunction, which may impair brain Ab clearance and also promote the influx of plasma Ab into the brain (reviewed by Winkler et al. 37 ). Based on these observations made in vivo and the literature evidence, we hypothesized that insulin regulates Ab trafficking at the BBB in L-A and A-L directions, and maintains Ab40:Ab42 ratios in plasma and brain compartments. Elucidating the mechanisms by which insulin conducts these functions in healthy subjects is critical to deciphering those pathological changes triggered by insulin resistance and hyperinsulinemia which are believed to aggravate AD pathology. Hence, the BBB trafficking of Ab proteins in L-A and A-L directions and insulin's role in shepherding these processes was investigated in polarized hCMEC/D3 cell monolayers, which is a widely used human BBB model. 17 However, due to a lack of pericytes in this model, the impact of endothelial and pericytic interactions on Ab trafficking and insulin's role in coordinating such interactions cannot be captured.
Insulin affects A trafficking at the BBB endothelium
In agreement with our in vivo observations, the luminal uptake and L-A permeability of Ab40 was enhanced, and that of Ab42 was reduced in hCMEC/D3 monolayers exposed to luminal insulin ( Figure 5(a) ). In contrast, the A-L permeability of 125 I-Ab40 was decreased, but the permeability of 125 I-Ab42 was increased upon abluminal insulin exposure. However, the A-L permeability differences between control and insulin-treated monolayers are modest, which is likely due to the lack of pericytes in the model. Despite this limitation, the agreement between in vitro and in vivo findings confirm the earlier reports that the BBB plays a preeminent role in maintaining plasma and brain Ab levels. 38 Moreover, our current findings suggest that insulin may modulate Ab trafficking and regulate Ab42:Ab40 ratios in plasma and brain. Shifts in Ab42:Ab40 ratios observed in familial AD patients were claimed to be due to mutations in APP and/or PS1 genes. 39 However, the current manuscript suggests a possibility that aberrant Ab42:Ab40 ratios could arise due to perturbation in Ab trafficking at the BBB. Thus, pathological conditions such as diabetes and obesity which are characterized by hyperinsulinemia, hyperlipidemia, and insulin resistance could engender pathological shifts in Ab42:Ab40 ratios.
We further investigated the effect of insulin on various stages of the transendothelial trafficking, primarily endocytosis and exocytosis, in hCMEC/D3 monolayers. The Ab endocytosis on the luminal side of the BBB is mediated by the RAGE receptor, expressed on the luminal membrane. 40 RAGE is known to play a central role in insulin resistance and is implicated in vascular complications associated with diabetes. 41 The endocytosis of Ab proteins on the abluminal side is handled by LRP-1, which is expressed on the abluminal membrane of the BBB. 42, 43 LRP1 is also expressed on the pericyte membrane and aid in the endocytosis of Ab proteins that are eventually degraded in the lysosomes. In addition, P-gp is expressed on the luminal membranes and is implicated in the brain Ab clearance. 19 Upon luminal insulin exposure, the LRP-1, RAGE, and P-gp immunofluorescence transiently increased in the polarized hCMEC/D3 monolayers ( Figure 6(b) ). The western blots have shown that the luminal insulin exposure did not alter the cellular levels of these receptors/transporters in hCMEC/D3 endothelial monolayers, whereas the plasma membrane distribution of RAGE, LRP-1, and P-gp increased (Figure 6(a) ). Similar studies were conducted on hepatocytes, where the luminal insulin exposure for various lengths of time was shown to induce the translocation of intracellular LRP-1 to the plasma membrane of hepatocytes and altered the peripheral clearance of Ab40. 11 However, a manifestation of this phenomenon in the BBB endothelium has been addressed for the first time in the current study.
The Ab endocytosis mediated by LRP1 and RAGE could progress via clathrin and/or caveolae-mediated pathways. Several studies have demonstrated the impact of insulin on these endocytotic processes in a variety of cells. 21, 23 Further, insulin was shown to differentially modulate clathrin versus caveolaemediated endocytosis of various ligands. For instance, in adipocytes, insulin treatment decreased the endocytosis of cholera toxin B, which is internalized by caveolae-mediated endocytosis. 44 In contrast, the endocytosis of transferrin 44 and a-2 macroglobulin, 45 which is mediated by clathrin-mediated endocytosis, increased. In this study, we have shown that luminal insulin exposure enhanced the uptake of FITCtransferrin by BBB endothelial cells (Figure 7(a) ), but reduced the uptake of AF647-cholera toxin B (Figure 7(b) ), a caveolae-mediated endocytosis marker. This differential modulation of endocytotic processes by insulin could extend beyond the specific ligands and may affect the endocytosis of other proteins such as Ab. We previously reported that Ab40 uptake by endothelial cells is predominantly clathrin-mediated, whereas Ab42 endocytosis is caveolae-mediated. 24, 46 Hence, differential effects of insulin observed on the luminal uptake of Ab40 and Ab42 could be due to the ability of insulin to selectively enhance clathrinmediated endocytosis and inhibit caveolae-mediated uptake. However, effects of insulin on Ab endocytosis do not entirely explain its differential impact on the brain clearances of Ab40 and Ab42. Insulin increases the expression of the endothelial LRP-1 receptor, which is purported to endocytose Ab peptides on the abluminal side. Although Ab40 has higher affinity to the LRP-1 receptor than does Ab42, 47 it is not evident how insulin could decrease Ab40 clearance from the brain. To resolve this dilemma, we also investigated the effect of insulin exposure on the exocytosis of Ab internalized by the endothelial cells. Insulin preferentially promoted the exocytosis of the internalized 125 I-Ab40 to the abluminal side, whereas the internalized 125 I-Ab42 was exocytosed to the luminal side ( Figure 5(b) ). While this may, to some extent, reconcile differential effects of insulin on 125 I-Ab40 and 125 I-Ab42 transcytosis at the BBB, the mechanism of endothelial exocytosis modulated by insulin to manifest these trafficking changes remains to be investigated.
The current study points out the impact of plasma insulin on Ab trafficking between plasma and brain compartments in healthy WT mice. Higher plasma insulin levels are observed in type-2 diabetes (T2DM) patients along with peripheral insulin resistance, and this could possibly affect the dynamic equilibrium between plasma and brain Ab levels. However, T2DM is also associated with hyperglycemia, hyperlipidemia, hypertension, as well as cerebrovascular pathologies resulting from the destructive remodeling of endothelium, pericytes, and smooth muscle cells. Owing to the lack of understanding of how these comorbidities influence AD pathology, the current findings may not be sufficient to establish a causal link between AD and T2DM. Further studies employing relevant T2DM and AD models are warranted to fully realize the pathological consequences of T2DM sequelae on Ab clearance and AD severity.
In summary, we have shown that intravenous insulin administration reduced the clearance and enhanced the plasma accumulation of Ab42, which was previously shown to trigger peripheral insulin resistance. Moreover, systemic administration of exogenous insulin differentially modulated the bi-directional trafficking of Ab40 and Ab42 at the BBB and altered Ab levels in the plasma and brain compartments. By invoking temporal and spatial changes in putative Ab receptors and cellular transport machinery within the BBB endothelium, insulin promotes 125 I-Ab40 accumulation in the brain but clears amyloidogenic 125 I-Ab42. Hence, there may be an intricate signaling/trafficking apparatus at the BBB responsive to fluctuations in insulin levels, arising from the circadian cycles and nutritional status (e.g. fasting), and Ab burden. Disruption of this regulatory network in cerebrovascular disease and metabolic disorders may exacerbate amyloidosis and insulin resistance, aggravate AD and CAA pathologies, and accelerate cognitive decline. Further studies are needed to verify these pathological consequences in WT and AD transgenic mouse models that manifest hyperinsulinemia and insulin resistance.
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